This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.Search in Google Scholar
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.Search in Google Scholar
Wojtyla C, Bertuccio P, Wojtyla A, La Vecchia C. European trends in breast cancer mortality, 1980-2017 and predictions to 2025. Eur J Cancer. 2021;152:4-17.Search in Google Scholar
Aggarwal S, Verma SS, Aggarwal S, Gupta SC. Drug repurposing for breast cancer therapy: Old weapon for new battle. Semin Cancer Biol. 2021;68:8-20.Search in Google Scholar
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75(4):805-16.Search in Google Scholar
Whittaker SR, Mallinger A, Workman P, Clarke PA. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther. 2017;173:83-105.Search in Google Scholar
Yarden Y, Elkabets M, editors. Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways. Resistance to Targeted Anti-Cancer Therapeutics; 2018.Search in Google Scholar
Al Bitar S, Gali-Muhtasib H. The Role of the Cyclin Dependent Kinase Inhibitor p21(cip1/waf1) in Targeting Cancer: Molecular Mechanisms and Novel Therapeutics. Cancers (Basel). 2019;11(10).Search in Google Scholar
Deng T, Yan G, Song X, Xie L, Zhou Y, Li J, et al. Deubiquitylation and stabilization of p21 by USP11 is critical for cell-cycle progression and DNA damage responses. Proc Natl Acad Sci U S A. 2018;115(18):4678-83.Search in Google Scholar
Shamloo B, Usluer S. p21 in Cancer Research. Cancers (Basel). 2019;11(8).Search in Google Scholar
Suvarna KS LC, Bancroft JD, Editors. Bancroft’s Theory and Practice of Histological Techniques. 8th edition. Churchill Livingstone/Elsevier Science. 2018.Search in Google Scholar
Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2): 181-5.Search in Google Scholar
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-47.Search in Google Scholar
Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155-68.Search in Google Scholar
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241-56.Search in Google Scholar
Focke CM, Burger H, van Diest PJ, Finsterbusch K, Glaser D, Korsching E, et al. Interlaboratory variability of Ki67 staining in breast cancer. Eur J Cancer. 2017;84: 219-27.Search in Google Scholar
Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. Breast Care (Basel). 2015;10(2):124-30.Search in Google Scholar
Gimenez-Bastida JA, Avila-Galvez M, Espin JC, Gonzalez-Sarrias A. Conjugated Physiological Resveratrol Metabolites Induce Senescence in Breast Cancer Cells: Role of p53/p21 and p16/Rb Pathways, and ABC Transporters. Mol Nutr Food Res. 2019;63(22):e1900629.Search in Google Scholar
Kashyap D, Kaur H. Cell-free miRNAs as non-invasive biomarkers in breast cancer: Significance in early diagnosis and metastasis prediction. Life Sci. 2020;246: 117417.Search in Google Scholar
Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018; 5(2):77-106.Search in Google Scholar
Aggarwal V, Kashyap D, Sak K, Tuli HS, Jain A, Chaudhary A, et al. Molecular Mechanisms of Action of Tocotrienols in Cancer: Recent Trends and Advancements. Int J Mol Sci. 2019;20(3).Search in Google Scholar
Zohny SF, Al-Malki AL, Zamzami MA, Choudhry H. p21(Waf1/Cip1): its paradoxical effect in the regulation of breast cancer. Breast Cancer. 2019;26(2):131-7.Search in Google Scholar
Wei CY, Tan QX, Zhu X, Qin QH, Zhu FB, Mo QG, et al. Expression of CDKN1A/p21 and TGFBR2 in breast cancer and their prognostic significance. Int J Clin Exp Pathol. 2015;8(11):14619-29.Search in Google Scholar
Jassim MMA, Rasool KH, Mahmood MM. p53, p21, and cyclin d1 protein expression patterns in patients with breast cancer. Vet World. 2021;14(10):2833-8.Search in Google Scholar
Zohny SF, Baothman OA, El-Shinawi M, Al-Malki AL, Zamzami MA, Choudhry H. The KIP/CIP family members p21^{Waf1/Cip1} and p57^{Kip2} as diagnostic markers for breast cancer. Cancer Biomark. 2017;18(4): 413-23.Search in Google Scholar
Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F, et al. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapsefree survival. Br J Cancer. 1996;74(2):208-15.Search in Google Scholar
Bankfalvi A, Tory K, Kemper M, Breukelmann D, Cubick C, Poremba C, et al. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. Pathol Res Pract. 2000;196(7):489-501.Search in Google Scholar
Mansouri S, Esmaeili R, Kaviani A, Rezaei M, Abdoli N, Mokhtari-Hesari P, et al. The Interaction Between the Expression of Proliferative Biomarkers and Clinical Characteristics in Breast Cancer. Multidisciplinary Cancer Investigation. 2018;2(2):20-8.Search in Google Scholar
Balbin M, Hannon GJ, Pendas AM, Ferrando AA, Vizoso F, Fueyo A, et al. Functional analysis of a p21WAF1,CIP1,SDI1 mutant (Arg94 --> Trp) identified in a human breast carcinoma. Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases. J Biol Chem. 1996;271(26):15782-6.Search in Google Scholar
Bedir R, Gucer H, Sehitoglu I, Yurdakul C, Bagc? P, Ustuner P. The Role of p16, p21, p27, p53 and Ki-67 Expression in the Differential Diagnosis of Cutaneous Squamous Cell Carcinomas and Keratoacanthomas: An Immunohistochemical Study. Balkan Med J. 2016; 33(2):121-7.Search in Google Scholar
Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, et al. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with longterm follow-up. Clin Cancer Res. 1996;2(9):1591-9.Search in Google Scholar
Rey MJ, Fernandez PL, Jares P, Munoz M, Nadal A, Peiro N, et al. p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J Pathol. 1998;184(3):265-71.Search in Google Scholar
Hermeking H, Funk JO, Reichert M, Ellwart JW, Eick D. Abrogation of p53-induced cell cycle arrest by c- Myc: evidence for an inhibitor of p21WAF1/CIP1/SDI1. Oncogene. 1995;11(7):1409-15.Search in Google Scholar
Lin D, Fiscella M, O'Connor PM, Jackman J, Chen M, Luo LL, et al. Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest. Proc Natl Acad Sci U S A. 1994;91(21):10079-83.Search in Google Scholar
Barboule N, Baldin V, S JO, Vidal S, Valette A. Increased level of p21 in human ovarian tumors is associated with increased expression of cdk2, cyclin A and PCNA. Int J Cancer. 1998;76(6):891-6.Search in Google Scholar
Cai K, Dynlacht BD. Activity and nature of p21(WAF1) complexes during the cell cycle. Proc Natl Acad Sci U S A. 1998;95(21):12254-9.Search in Google Scholar
Brugarolas J, Bronson RT, Jacks T. p21 is a critical CDK2 regulator essential for proliferation control in Rbdeficient cells. J Cell Biol. 1998;141(2):503-14.Search in Google Scholar
Hiyama H, Iavarone A, LaBaer J, Reeves SA. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene. 1997;14(21):2533-42.Search in Google Scholar
Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, et al. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res. 2004; 10(11):3815-24.Search in Google Scholar
Diaz Flaque MC, Vicario R, Proietti CJ, Izzo F, Schillaci R, Elizalde PV. Progestin drives breast cancer growth by inducing p21(CIP1) expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2. Steroids. 2013;78(6):559-67.Search in Google Scholar
Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, et al. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochem Biophys Res Commun. 2010;403(1):103-7.Search in Google Scholar
